RxDoctor Payments Data

Mehr Iqbal, MD

Neurology · Romeoville, ILNPI 1013264035

Payments from drug & device makers

$1,764in general payments, 2019–2025

Across 76 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$414
  • Johnson & Johnson$272
  • AbbVie$243
  • Neurocrine Biosciences, Inc.$216
  • Lundbeck LLC$113
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$93
  • plus $412 from 11 others

What the payments were for

  • Food & beverage$1,764100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,764 in reported general payments places this provider in the 60th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$101,701
Medicare patients
206
Services billed
909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole20$30,878
TrintellixVortioxetine Hydrobromide20$18,307
Lurasidone Hcl29$14,575
Duloxetine Hcl366$9,444
Venlafaxine Hcl ErVenlafaxine Hcl415$7,376
Bupropion XlBupropion Hcl371$6,176
PristiqDesvenlafaxine Succinate13$5,724
Bupropion Hcl302$5,248
Sertraline Hcl606$5,001
Desvenlafaxine Succinate ErDesvenlafaxine Succinate82$4,847
Aripiprazole216$4,293
Mirtazapine248$4,074
Quetiapine Fumarate352$3,997
Clonazepam457$3,750
Trazodone Hcl507$3,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$414$30,87820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 790 neurology providers in Illinois.

Other neurology in Romeoville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →